Azacytidine

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Azacytidine is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

8/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed5 · 42%

Recruiting3 · 25%

Unknown status2 · 17%

Withdrawn1 · 8%

Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Recruiting·—·Phase 2·NCT05317000·50 enrolled

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

Recruiting·LLudwig-Maximilians - University of Munich·Phase 2·NCT04913922·30 enrolled

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting·UUniversity of Virginia·Phase 2·NCT04747236·50 enrolled

Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

Not yet recruiting·PPETHEMA Foundation·Phase 3·NCT07478991·376 enrolled

Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

Completed·HHelsinki University Central Hospital·Phase 2·NCT04267081·104 enrolled

Phase II 5-Azacytidine Plus VPA Plus ATRA

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00326170·34 enrolled

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00339196·25 enrolled

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00439673·62 enrolled

PKC412 and 5-Azacytidine

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01202877·54 enrolled

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

Withdrawn·UUniversity of Pittsburgh·Phase 2·NCT02204020

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Unknown status·AAssistance Publique Hopitaux De Marseille·N/A·NCT02489929·35 enrolled

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS

Unknown status·GGroupe Francophone des Myelodysplasies·Phase 1/2·NCT01718366·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)